英文名称 | CAS号 | 中文名 | 中文别名 | 分子式 | 分子量 | EINECS号 |
---|---|---|---|---|---|---|
BQU 57
|
1637739-82-2 |
BQU57
|
|
C16H13F3N4O |
334.29583 | |
BMS303141
|
943962-47-8 |
BMS303141
|
BMS303141;BMS 303141;3,5-二氯-2-羟基-N-(4-甲氧基[1,1'-联苯]-3-基)苯磺酰胺;CS-887
|
C19H15Cl2NO4S |
424.2977 | |
BIX 01294
|
935693-62-2 |
BIX 01294
|
2-(六氢-4-甲基-1H-1,4-二氮杂卓-1-基(-6,7-二甲氧基-N-[1-(苯基甲基(-4-哌啶基]-4-喹唑啉胺;2-(HEXAHYDRO-4-METHYL-1H-1,4-DIAZEPIN-1-YL(-6,7-DIMETHOXY-N-[1-(PHENYLMETHYL(-4-PIPERIDINYL]-4-QUINAZOLINAMINE 三盐酸盐 水合物;CS-207;BIX 01294 三盐酸盐 水合物;BIX-01294;BIX 01294;BIX01294;N-(1-苄基哌啶-4-基(-6,7-二甲氧基-2-(4-甲基-1,4-二氮杂环庚-1-基(喹唑啉-4-胺
|
C28H38N6O2.3ClH.H2O |
618.046 | |
BI-D1870
|
501437-28-1 |
BI-D1870
|
BID1870;BI-D 1870;2-[(3,5-二氟-4-羟基苯基)氨基]-7,8-二氢-5,7-二甲基-8-(3-甲基丁基)-6(5H)-蝶啶酮
|
C19H23F2N5O2 |
391.42 | |
BI6727 (Volasertib)
|
755038-65-4 |
Volasertib (BI 6727)
|
CS-552;VOLASERTIB (BI 6727);BI 6727;BI-6727;BI6727;伏拉塞替 250MG;伏拉塞替;N-[反式-4-[4-(环丙基甲基)-1-哌嗪基]环己基];N-[反式-4-[4-(环丙基甲基)-1-哌嗪基]环己基]-4-[[(7R)-7-乙基-5,6,7,8-四氢-5-甲基-8-异丙基-6-氧代-2-蝶啶基]氨基]-3-甲氧基苯甲酰胺;BI 6727;BI-6727;BI6727;CS-1612
|
C34H50N8O3 |
618.8126 | 813-258-1 |
Balicatib
|
354813-19-7 |
BALICATIB
|
BALICATIB;N-(1-(氰甲基氨甲酰)环己基)-4-(4-丙基哌嗪-1-基)苯甲酰胺
|
C23H33N5O2 |
411.55 | 200-256-5 |
γ-Secretase Inhibitor IV
|
797035-11-1 |
BETA-SECRETASE INHIBITOR IV
|
|
C31H38N4O5S |
578.72222 | |
AZD1080
|
612487-72-6 |
AZD1080
|
5-[[(4-碘苯基)氨基]亚甲基]-2,2-二甲基-1,3-二恶烷-4,6-二酮;2-羟基-3-[5-[(吗啉-4-基)甲基]吡啶-2-基]-1H-吲哚-5-甲腈;CS-809;AZD 1080;AZD-1080;2-羟基-3-[5-(吗啉-4-甲基)吡啶-2-基]-1H-吲哚-5-甲腈
|
C19H18N4O2 |
334.37182 | |
AZ 3146
|
1124329-14-1 |
AZ3146
|
9-环戊基-7,9-二氢-2-[[2-甲氧基-4-[(1-甲基-4-哌啶基)氧基]苯基]氨基]-7-甲基-8H-嘌呤-8-酮;9-环戊基-2-[[2-甲氧基-4-[(1-甲基哌啶-4-基)氧基]-苯基]氨基]-7-甲基-7,9-二氢-8H-嘌呤-8-酮
|
C24H32N6O3 |
453 | |
AVL-292
|
1202757-89-8 |
AVL292
|
CC-292;AVL292;AVL-292;AVL 292;CC-292;AVL292;AVL-292;AVL 292;SPEBRUTINIB;CS-733;N-[3-[[5-氟-2-[[4-(2-甲氧基乙氧基(苯基]氨基]-4-嘧啶基]氨基]苯基]-2-丙烯酰胺
|
C22H22FN5O3 |
423.440183 | |
Aurora A Inhibitor I
|
1158838-45-9 |
Aurora A Inhibitor I
|
N-(2-氯苯基)-4-[[2-[[4-[2-(4-乙基-1-哌嗪基)-2-氧代乙基]苯基]氨基]-5-氟-4-嘧啶基]氨基]苯甲酰胺
|
C31H31ClFN7O2 |
588.0749432 | |
Atglistatin
|
1469924-27-3 |
ATGLISTATIN
|
CS-1024;1'-联苯]-3-基]-N;N'-[4'-(二甲基氨基)[1;3-(4'-(DIMETHYLAMINO)BIPHENYL-3-YL)-1,1-DIMETHYLUREA;N'-[4'-(二甲基氨基)[1,1'-联苯]-3-基]-N,N-二甲基脲;1,1-二甲基-3-[4'-(二甲氨基)-联苯-3-基]脲
|
C17H21N3O |
283.36814 | 200-256-5 |
ATB 346
|
1226895-20-0 |
ATB 346
|
ATB346;ATB 346;ABT-346 抑制剂;CS-1282;4-CARBAMOTHIOYLPHENYL 2-(6-METHOXYNAPHTHALEN-2-YL)PROPANOATE
|
C21H19NO3S |
365.44546 | |
1-cyclopropyl-3-[(3Z)-3-[5-(morpholin-4-ylmethyl)benzimidazol-2-ylidene]-1,2-dihydropyrazol-4-yl]urea
|
896466-04-9 |
AT9283
|
CS-48;AT-9283;AT 9283;1-环丙基-3-(3-(5-(吗啉甲基)-1H-苯并[D]咪唑-2-基)-1H-吡唑-4-基)脲
|
C19H23N7O2 |
381.43162 | |
AT13148
|
1056901-62-2 |
AT13148
|
AT-13148;AT 13148;(+)-(S)-2-氨基-1-(4-氯苯基)-1-[4-(1H-吡唑-4-基)苯基]乙醇;CS-1252
|
C17H16ClN3O |
313.78144 | |
ASP3026
|
1097917-15-1 |
ASP3026
|
N2-[2-甲氧基-4-[4-(4-甲基-1-哌嗪基)-1-哌啶基]苯基]-N4-[2-[(1-甲基乙基)磺酰基]苯基]-1,3,5-三嗪-2,4-二胺
|
C29H40N8O3S |
580.7447 | 200-258-5 |
AR-A 014418
|
487021-52-3 |
AR-A 014418
|
CS-1021;N-(4-甲氧基苄基)-N'-(5-硝基-1,3-噻唑-2-基)脲;AR-AO 14418;AR 0133418;AR 014418;GSK 3Β INHIBITOR;AR 0133418;GSK 3Β INHIBITOR VIII;AR 014418;GSK-3BETA 抑制剂 VIII
|
C12H12N4O4S |
308.317 | |
AR-42 (HDAC-42)
|
935881-37-1 |
AR-42
|
CS-15;(S)-(+)-N-羟基-4-(3-甲基-2-苯基丁酰氨基)苯甲酰胺
|
C18H20N2O3 |
312.363 | 802-219-4 |
Apoptozole
|
1054543-47-3 |
CS-2225
|
APOPTOSIS ACTIVATOR VII;CS-2225
|
C33H25F6N3O3 |
625.560319 | |
Apoptosis Activator 2
|
79183-19-0 |
APOPTOSIS ACTIVATOR 2
|
MDK83190;1-(3,4-二氯苄基)-1H-吲哚-2,3-二酮;凋亡活化剂 2;CS-572;凋亡激活剂 2;细胞凋亡激活剂2,一种细胞色素C半胱天冬酶活化剂和凋亡诱导物
|
C15H9Cl2NO2 |
306.14 | 200-256-5 |